V V S Rajendra Prasad
Overview
Explore the profile of V V S Rajendra Prasad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdary P, Puppala E, Putta C, Maddila J, Pulavarthy V, Prasad V, et al.
ACS Appl Bio Mater
. 2025 Jan;
8(2):1594-1606.
PMID: 39876608
The Janus kinase inhibitor tofacitinib (TOF) is an FDA-approved drug for rheumatoid arthritis (RA) treatment, but its long-term oral use leads to significant systemic side effects. The present research aimed...
2.
Gade D, Makkapati A, Yarlagadda R, Peters G, Sastry B, Prasad V
Comput Biol Chem
. 2018 Mar;
74:63-75.
PMID: 29547875
Overexpression of P-glycoprotein (P-gp) leads to the emergence of multidrug resistance (MDR) in cancer treatment. Acridones have the potential to reverse MDR and sensitize cells. In the present study, we...
3.
Prasad V, Reddy G, Kathmann I, Amareswararao M, Peters G
Bioorg Chem
. 2015 Dec;
64:51-8.
PMID: 26657603
A series of nitric oxide donating acridone derivatives are synthesized and evaluated for in vitro cytotoxic activity against different sensitive and resistant cancer cell lines MCF7/Wt, MCF7/Mr (BCRP overexpression) and...
4.
Prasad V, Reddy G, Appaji D, Peters G, Mayur Y
J Mol Graph Model
. 2013 Feb;
40:116-24.
PMID: 23388503
Calmodulin inhibitors have proved to play a significant role in sensitizing MDR cancer cells by interfering with cellular drug accumulation. The present investigation focuses on the evaluation of in vitro...
5.
Prasad V, Peters G, Lemos C, Kathmann I, Mayur Y
Eur J Pharm Sci
. 2011 May;
43(4):217-24.
PMID: 21565270
A series of novel N(10)-substituted acridone derivatives bearing alkyl side-chain with tertiary amine groups at the terminal position were evaluated for their in vitro cytotoxic effects against drug sensitive and...
6.
Purohit M, Prasad V, Mayur C
Arch Pharm (Weinheim)
. 2011 Apr;
344(4):248-54.
PMID: 21469174
A new series of 1,4-bis[5-(5-mercapto-1,3,4-oxadiazol-2-yl-methyl)-thio-4-substituted-1,2,4-triazol-3-yl]-butane 7-12 and 1,4-bis[5-(1-oxo-1-(3,5 dimethyl pyrazol-1-yl)-methyl)-thio-4-substitued-1,2,4-triazol-3-yl]-butane 13-18 were prepared from 1,4-bis(5[hydrazinocarbonylmethylthio]-4-substituted-1,2,4-triazol-3-yl) butane based derivativess were synthesized 1-6. All the synthesized compounds were characterized by IR, NMR...
7.
Mayur Y, Peters G, Prasad V, Lemo C, Sathish N
Curr Cancer Drug Targets
. 2009 May;
9(3):298-306.
PMID: 19442050
Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some...
8.
Mayur Y, Ahmad O, Prasad V, Purohit M, Srinivasulu N, Kumar S
Med Chem
. 2008 Sep;
4(5):457-65.
PMID: 18782042
A series of N10-substituted-2-methyl acridone derivatives are synthesized and are examined for its ability to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in breast cancer cell lines MCF-7 and MCF-7/Adr....
9.
Prasad V, Rao J, Giri R, Sathish N, Kumar S, Mayur Y
Chem Biol Interact
. 2008 Jul;
176(2-3):212-9.
PMID: 18638463
We report herein in vitro anti-proliferative activity and duplex DNA complex studies of a series of N10-substituted acridone derivatives. All the molecules have been designed on the basis of the...